Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The Evolving Paradigm of Prostate Cancer Screening.

Albertsen PC.

JAMA Netw Open. 2019 Aug 2;2(8):e198392. doi: 10.1001/jamanetworkopen.2019.8392. No abstract available.

PMID:
31390029
2.

Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.

Bell MA, Campbell JD, Joice G, Sopko NA, Burnett AL.

World J Mens Health. 2018 May;36(2):103-109. doi: 10.5534/wjmh.170007. Epub 2018 Mar 22. Review.

3.

Prostate cancer: an evolving paradigm.

Caso JR, Mouraviev V, Tsivian M, Polascik TJ, Moul JW.

J Endourol. 2010 May;24(5):805-9. doi: 10.1089/end.2009.0539.

PMID:
20367442
4.

Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.

Rodriguez JF, Eggener SE.

Radiol Clin North Am. 2018 Mar;56(2):187-196. doi: 10.1016/j.rcl.2017.10.002. Epub 2017 Nov 26. Review.

PMID:
29420975
5.

Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.

Payne H, Cornford P.

Urol Oncol. 2011 Nov-Dec;29(6):593-601. doi: 10.1016/j.urolonc.2009.11.003. Epub 2010 Jan 8. Review.

PMID:
20060331
6.

Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd.

Cancer Treat Rev. 2012 Dec;38(8):956-67. doi: 10.1016/j.ctrv.2012.05.005. Epub 2012 Jun 15. Review.

7.

[A paradigm shift for prostate cancer diagnostics].

Bratt O.

Lakartidningen. 2018 Oct 23;115. pii: FCFW. Swedish.

8.

Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy.

David J, Kamrava M.

J Clin Oncol. 2019 Feb 10;37(5):441. doi: 10.1200/JCO.18.01482. Epub 2018 Dec 28. No abstract available.

PMID:
30592643
9.

Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA era.

Eisenberger MA.

Urol Oncol. 2008 Jul-Aug;26(4):406-7. doi: 10.1016/j.urolonc.2007.11.001. No abstract available.

PMID:
18593618
10.

Prostate cancer screening.

Ragsdale JW 3rd, Halstater B, Martinez-Bianchi V.

Prim Care. 2014 Jun;41(2):355-70. doi: 10.1016/j.pop.2014.02.009. Epub 2014 Mar 26. Review.

PMID:
24830612
11.

Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Grenabo Bergdahl A, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J.

Eur Urol. 2016 Oct;70(4):566-573. doi: 10.1016/j.eururo.2015.12.006. Epub 2015 Dec 24. Erratum in: Eur Urol. 2017 Feb;71(2):e81.

12.

Prostate cancer: current and evolving strategies.

Cersosimo RJ, Carr D.

Am J Health Syst Pharm. 1996 Feb 15;53(4):381-96; quiz 446-8. Review.

PMID:
8673658
13.

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

Morgan T, Palapattu G, Wei J.

Curr Urol Rep. 2015 Sep;16(9):63. doi: 10.1007/s11934-015-0537-3. Review.

PMID:
26169584
14.

MR Imaging for Prostate Cancer Screening and Active Surveillance.

Druskin SC, Macura KJ.

Radiol Clin North Am. 2018 Mar;56(2):251-261. doi: 10.1016/j.rcl.2017.10.006. Epub 2017 Dec 6. Review.

PMID:
29420980
15.

Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies.

Juloori A, Shah C, Stephans K, Vassil A, Tendulkar R.

Prostate Cancer. 2016;2016:2420786. doi: 10.1155/2016/2420786. Epub 2016 May 23. Review.

16.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.

Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

PMID:
27568654
17.

The evolving biology and treatment of prostate cancer.

Taichman RS, Loberg RD, Mehra R, Pienta KJ.

J Clin Invest. 2007 Sep;117(9):2351-61.

18.

Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making.

Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.

Radiol Clin North Am. 2018 Mar;56(2):239-250. doi: 10.1016/j.rcl.2017.10.007. Epub 2017 Dec 11. Review.

PMID:
29420979
19.

Evolving Recommendations on Prostate Cancer Screening.

Brawley OW, Thompson IM Jr, Grönberg H.

Am Soc Clin Oncol Educ Book. 2016;35:e80-7. doi: 10.14694/EDBK_157413.

20.

Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.

Vargas HA, Grimm J, F Donati O, Sala E, Hricak H.

Eur Radiol. 2015 May;25(5):1294-302. doi: 10.1007/s00330-014-3539-5. Epub 2015 Feb 20. Review.

Supplemental Content

Support Center